Humacyte rises 6% as regulators reviewing bioengineered human tissue asset

seekingalpha11-09

sanjeri Humacyte (NASDAQ:HUMA) is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel (ATEV) for vascular trauma is ongoing. The news provides a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482437444?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1867575053/image_1867575053.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-11-09 03:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482437444","market":"fut","top_or_hot":-1,"title":"Humacyte rises 6% as regulators reviewing bioengineered human tissue asset","media":"seekingalpha","content":"<div>\n<p>sanjeri Humacyte (NASDAQ:HUMA) is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel (ATEV) for vascular trauma is ongoing. The news provides a ...</p>\n\n<a href=\"https://seekingalpha.com/news/4267719-humacyte-rises-6-percent-regulators-reviewing-bioengineered-human-tissue-asset\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humacyte rises 6% as regulators reviewing bioengineered human tissue asset</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumacyte rises 6% as regulators reviewing bioengineered human tissue asset\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 03:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4267719-humacyte-rises-6-percent-regulators-reviewing-bioengineered-human-tissue-asset><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>sanjeri Humacyte (NASDAQ:HUMA) is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel (ATEV) for vascular trauma is ongoing. The news provides a ...</p>\n\n<a href=\"https://seekingalpha.com/news/4267719-humacyte-rises-6-percent-regulators-reviewing-bioengineered-human-tissue-asset\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://seekingalpha.com/news/4267719-humacyte-rises-6-percent-regulators-reviewing-bioengineered-human-tissue-asset","article_id":"2482437444","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1867575053/image_1867575053.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482437444","pubTimestamp":1731094466,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"sanjeri Humacyte  is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel  for vascular trauma is ongoing. The news provides a sigh of relief after the company said in August that the agency would need additional time to review the application. The original action date was Aug. 10.  BTIG analyst Ryan Zimmerman, who rates Humacyte a buy, wrote that the development is a positive sign and \"suggests that there is forward progress.\" And while he expects ATEV will win approval, he added the \"timing is difficult to handicap.\"","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","HUMA":"Humacyte, Inc.","BK4139":"生物科技"},"translate_title":"监管机构审查生物工程人体组织资产，Humacyte股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":0.9},"content_text":"sanjeri Humacyte (NASDAQ:HUMA) is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel (ATEV) for vascular trauma is ongoing. The news provides a sigh of relief after the company said in August that the agency would need additional time to review the application. The original action date was Aug. 10.  BTIG analyst Ryan Zimmerman, who rates Humacyte a buy, wrote that the development is a positive sign and \"suggests that there is forward progress.\" And while he expects ATEV will win approval, he added the \"timing is difficult to handicap.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482437444"}